Home > Insider Trading > Filing (0000899243-20-020427)

Filing Details

Accession Number:: 0000899243-20-020427
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-24 18:59:01
Reporting Period:: 2020-07-22

Accepted Time:: 2020-07-24 18:59:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1274792	Merrimack Pharmaceuticals Inc	MACK	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1548707	Newtyn Partners, Lp	60 East 42Nd Street, 9Th Floor New York NY 10165	No	No	No	Yes
1548709	Newtyn Te Partners, Lp	60 East 42Nd Street, 9Th Floor New York NY 10165	No	No	No	Yes
1569241	Newtyn Management, Llc	60 East 42Nd Street, 9Th Floor New York NY 10165	No	No	No	Yes
1788608	G. Noah Levy	60 East 42Nd Street, 9Th Floor New York NY 10165	Yes	No	No	Yes
1789643	Newtyn Capital Partners, Lp	60 East 42Nd Street, 9Th Floor New York NY 10165	No	No	No	Yes
1789647	Ledo Capital, Llc	60 East 42Nd Street, 9Th Floor New York NY 10165	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-07-22	46,745	$3.20	739,759	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-07-22	56,606	$3.04	796,365	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-07-22	33,435	$3.20	540,027	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-07-22	40,488	$3.04	580,515	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Footnotes

The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
The purchase of the securities referenced in this Form 4 were conducted in a private transaction between Gary Crocker and certain family members and affiliates as the sellers and each of Western Standard Partners, L.P., Western Standard Partners QP, L.P., Newtyn Partners, LP, and Newton Partners TE, LP as the purchasers. Gary Crocker is President and Chairman of Merrimack Pharmaceuticals, Inc. (the "Company"). Eric Andersen, a member of the Company's Board of Directors, is Managing Member of Western Standard LLC, the investment manager for each of Western Standard Partners L.P. and Western Standard Partners QP L.P. Noah Levy, a member of the Company's Board of Directors, is Managing Member of Newtyn Management, LLC, the investment manager for Newtyn Partners, LP, and Newton Partners TE, LP.